ly2780301
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2010 (NCT01115751)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Serine/threonine-protein kinase AKTINHIBITOR
Serine/threonine-protein kinase AKT inhibitor
- Ribosomal protein S6 kinase (P70S6K)INHIBITOR
Ribosomal protein S6 kinase (P70S6K) inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545134 ↗
Also known as
- ly2780301
- ly-2780301
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01980277 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2014 | Institut Paoli-Calmettes |
| NCT02018874 | Phase 1 | Sep 1, 2013 | Institut Gustave Roussy |
| NCT01115751 | Phase 1 | Mar 1, 2010 | Eli Lilly |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 1 | 1 | 1 | 2010 |
| Institut Gustave Roussy | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Institut Paoli-Calmettes | Academic/Hospital | 1 | 1 | 1 | 2014 |
3 organizations
Page 1 / 1